News

Epocal Announces FDA Clearance of Glucose Test

Press Release
Ottawa, Ontario
August 11, 2009

OTTAWA, ON Canada - Aug. 11, 2009 -- Epocal, Inc., a leading edge provider of point
of care technology, announced today that it has received U.S. Food and Drug
Administration (FDA) clearance to market its new glucose test on the epoc
Blood Analysis System.  Glucose measurements are used for the diagnosis and
treatment of carbohydrate metabolism disorders including diabetes mellitus and
idiopathic hypoglycemia, and of pancreatic islet cell tumors.  The addition of
glucose to the epoc BGEM Test Card, which includes in vitro diagnostic tests
for pH, pO2, pCO2, Na, K, iCa and Hct (plus calculated values), further
expands the clinical utility of the Company's point of care blood gas and
electrolyte platform.

"The FDA clearance of glucose represents one of many milestones to come for
Epocal and for healthcare as we continue to expand the test menu of the first
wireless and cost effective point of care testing system." said Imants Lauks,
Epocal President and Founder.  "We are very excited to offer an award winning
technology that enables hospitals worldwide to improve the delivery of patient
care, reduce their operating expenses and operate more efficiently."

About Epocal, Inc.
Epocal, Inc., headquartered in Ottawa, ON, Canada with U.S. Sales and
Marketing operations located in Horsham, PA, develops, manufactures and
markets the epoc Blood Analysis System.  epoc (enterprise point of care) is
healthcare's first cost effective point of care testing solution to leverage
SmartCard(TM) technology and the power of wireless communication to provide
critical caregivers with real-time, laboratory quality test results at the
patient's bedside.

Additional information about the epoc System and Epocal, Inc. is available on
the Company's website - www.epocal.com